Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S453000
Reexamination Certificate
active
07910616
ABSTRACT:
Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.
REFERENCES:
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5576012 (1996-11-01), Bauer et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5756764 (1998-05-01), Fenteany et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 6133308 (2000-10-01), Soucy et al.
patent: 6147223 (2000-11-01), Fenteany et al.
patent: 6214862 (2001-04-01), Fenteany et al.
patent: 6271199 (2001-08-01), Brand et al.
patent: 6294560 (2001-09-01), Soucy et al.
patent: 6333358 (2001-12-01), Nakazato et al.
patent: 6335358 (2002-01-01), Fenteany et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6458825 (2002-10-01), Fenteany et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: 6566553 (2003-05-01), Soucy et al.
patent: 6645999 (2003-11-01), Schreiber et al.
patent: 6794516 (2004-09-01), Soucy et al.
patent: 6838477 (2005-01-01), Schreiber et al.
patent: 6849743 (2005-02-01), Soucy et al.
patent: 7144723 (2006-12-01), Fenical et al.
patent: 7176232 (2007-02-01), Fenical et al.
patent: 7176233 (2007-02-01), Fenical et al.
patent: 7179834 (2007-02-01), Fenical et al.
patent: 7183417 (2007-02-01), Corey
patent: 7276530 (2007-10-01), Potts et al.
patent: 7371875 (2008-05-01), Xiao et al.
patent: 7544814 (2009-06-01), Potts et al.
patent: 7572606 (2009-08-01), Lam et al.
patent: 7579371 (2009-08-01), Palladino et al.
patent: 7635712 (2009-12-01), Fenical et al.
patent: 2001/0002391 (2001-05-01), Brand et al.
patent: 2001/0051654 (2001-12-01), Elliott et al.
patent: 2003/0157695 (2003-08-01), Fenical et al.
patent: 2004/0138196 (2004-07-01), Fenical et al.
patent: 2005/0049294 (2005-03-01), Palladino et al.
patent: 2005/0203029 (2005-09-01), Schubert et al.
patent: 2005/0203162 (2005-09-01), Xiao et al.
patent: 2005/0239866 (2005-10-01), Fenical et al.
patent: 2006/0008852 (2006-01-01), Fenical et al.
patent: 2006/0229353 (2006-10-01), Stadler et al.
patent: 2006/0264495 (2006-11-01), Palladino et al.
patent: 2006/0287520 (2006-12-01), Danishefsky et al.
patent: 2007/0004676 (2007-01-01), Palladino et al.
patent: 2007/0155815 (2007-07-01), Fenical et al.
patent: 2007/0161693 (2007-07-01), Corey
patent: 2007/0225350 (2007-09-01), Anderson et al.
patent: 2007/0249693 (2007-10-01), Ling et al.
patent: 2008/0070273 (2008-03-01), Fenical et al.
patent: 2008/0070969 (2008-03-01), Potts et al.
patent: 2008/0280968 (2008-11-01), Palladino et al.
patent: 2009/0062547 (2009-03-01), Romo et al.
patent: 2009/0069401 (2009-03-01), Fenical et al.
patent: 2009/0197937 (2009-08-01), Fenical et al.
patent: 2009/0234137 (2009-09-01), Ling et al.
patent: 2010/0144826 (2010-06-01), Fenical et al.
patent: 2010/0168046 (2010-07-01), Palladino et al.
patent: 2429163 (2002-06-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 99/09006 (1999-02-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 02/47610 (2002-06-01), None
patent: WO 2004/043374 (2004-05-01), None
patent: WO 2004/071382 (2004-08-01), None
patent: WO 2005/002572 (2005-01-01), None
patent: WO 2005/003137 (2005-01-01), None
patent: WO 2005/094423 (2005-10-01), None
patent: WO 2005/099687 (2005-10-01), None
patent: WO 2006/005551 (2006-01-01), None
patent: WO 2006/028525 (2006-03-01), None
patent: WO 2006/060609 (2006-06-01), None
patent: WO 2006/060676 (2006-06-01), None
patent: WO 2006/060809 (2006-06-01), None
patent: WO 2006/118973 (2006-11-01), None
patent: WO 2007/021897 (2007-02-01), None
patent: WO 2007/033039 (2007-03-01), None
patent: WO 2007/130404 (2007-11-01), None
patent: WO 2007/138116 (2007-12-01), None
patent: WO 2008/137780 (2008-11-01), None
“Heteroatom.” Merriam-Webster Online Dictionary. 2010. Merriam-Webster Online. Accessed Jun. 16, 2010. <http://merriam-webster.com/dictionary/heteroatom>.
Adams, et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents,”Cancer Res., (1999) 59:2615-2622.
Adams, J., “Preclinical Development of Velcade (Bortezomib; formerly PS-341) for Multiple Myeloma”—MMRF Abstract,Euro. J. Haematology, (2003) 70:263 & 265.
Adams, J., “Proteasome Inhibitors as New Anticancer Drugs,”Curr. Opin. Oncol., (2002) 14:628-72.
Alessandri, et al., “Mobilization of Capillary Endothelium in Vitro Induced by Effectors of Angiogenesis In Vivo,”Cancer Res., (1983) 43(4):1790-1797.
Alm, et al., “Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes,”Prog. Clin. Biol. Res., (1989) 312:447-58.
Ando et al., Silver Fluoride Supported on Calcium Fluoride. Improved Fluorination and Halofluorination Reactions, Chem Lttrs. (1988) 11: 1877-1878.
Beers et al. (Eds.), “Bacterial Diseases,”The Merck Manual of Diagnosis and Therapy, (1999) The Merck Research Laboratories, Whitehouse Station N.J., Section 13, Chapter 157: pp. 1157-1158.
Beers et al. (Eds.), “Parasitic Infections,”The Merck Manual of Diagnosis and Therapy, (1999) The Merck Research Laboratories, Whitehouse Station N.J., Section 13, Chapter 161: pp. 1241-1252.
Beers et al. (Eds.),The Merck Manual of Diagnosis and Therapy, 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 397-398, 948-949, 1916, 1917, 1974, 1975, and 1978-1983.
Beers et al. (Eds.),The Merck Manual of Diagnosis and Therapy, 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 1193-1201 & 1204.
Beers, et al. (Eds), “The Merck Manual of Diagnosis and Therapy”, 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 1085-1088, 1101-1135, and 1237-1276.
Bernan, et al. “Marine Microorganisms as a Source of New Natural Products,”Advances in Applied Microbiology, (1997) 43:57-90.
Bhalla, et al., “High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells,”Blood, (1993) 82(10):3133-3140.
Bicknell, et al. (Eds.),Tumour Angiogenesis, Oxford University Press, New York (1997), Table of Contents, pp. 5.
Blum, et al., “Adriamycin: A New Anticancer Drug with Significant Clinical Activity,”Ann Intern Med, (1974) 80(2):249-259.
Blunt, et al., “Marine Natural Products,”Nat. Prod. Rep., (2003) 20:1-48.
Bodart, et al., “Anthrax, MEK and Cancer,”Cell Cycle, (2002) 1:10-15.
Bradley, et al., “Identification of the Cellular Receptor for Anthrax Toxin,”Nature, (2001) 414:225-229.
Bull, et al., “Search and Discovery Strategies for Biotechnology: the Paradigm Shift,”Microbiol. Mol. Biol. Rev., (2000) 64(3):573-606.
Carey, Francis,Organic Chemistry, 2nd ed., McGraw Hill, Inc., New York (1992), pp. 328-331.
Chao et al., “Leaving Groups Extend the Duration of Proteasome Inhibition and Enhance the Potency of Salinosporamides”, Nereus Pharmaceuticals, Inc. Release (Feb. 2008), Poster circulated at Marine Natural Products Gordon Research Conference, Ventura, CA, 1 page.
Chauhan, et al., “A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib,”Cancer Cell, (2005) 8
Chao Ta-Hsiang
Macherla Venkat Rami Reddy
Manam Rama Rao
McArthur Katherine A.
Neuteboom Saskia Theodora Cornelia
Bianchi Kristin
Knobbe Martens Olson & Bear LLP
Nereus Pharmaceuticals Inc.
Saeed Kamal A
LandOfFree
Proteasome inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteasome inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteasome inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747045